FPHAX Holdings Information

FPHAX is a mutual fund with a total of 55 individual holdings. The top holdings are Eli Lilly and Company stock at 26.23%, GSK plc at 9.16%, Johnson & Johnson at 6.08%, Viatris at 5.40%, and UCB SA at 4.84%.

Total Holdings

Top 10 Percentage

74.26%

Asset Class

Equity

Fund Category

Health

Assets

1.50B

Forward PE Ratio

15.69

Breakdown by Asset Class

Top 25 Holdings

No.	Symbol	Name	% Weight	Shares
1	LLY	Eli Lilly and Company	26.23%	390,801
2	GSK	GSK plc	9.16%	2,438,760
3	JNJ	Johnson & Johnson	6.08%	368,600
4	VTRS	Viatris Inc.	5.40%	5,032,300
5	EBR: UCB	UCB SA	4.84%	248,300
6	SWX: ROP	Roche Holding AG	4.76%	162,670
7	MRK	Merck & Co., Inc.	4.70%	599,336
8	LON: AZN	AstraZeneca PLC	4.62%	343,650
9	LEGN	Legend Biotech Corporation	4.26%	2,522,300
10	GILD	Gilead Sciences, Inc.	4.21%	448,100
11	ELAN	Elanco Animal Health Incorporated	3.67%	2,283,500
12	JAZZ	Jazz Pharmaceuticals plc	3.55%	243,300
13	RPRX	Royalty Pharma plc	2.59%	718,900
14	MRNA	Moderna, Inc.	1.49%	452,400
15	BNTX	BioNTech SE	1.27%	170,453
16	NTLA	Intellia Therapeutics, Inc.	1.26%	1,297,900
17	BEAM	Beam Therapeutics Inc.	1.14%	523,400
18	XENE	Xenon Pharmaceuticals Inc.	0.91%	226,000
19	OCUL	Ocular Therapeutix, Inc.	0.90%	1,331,717
20	PTCT	PTC Therapeutics, Inc.	0.76%	161,700
21	IDXX	IDEXX Laboratories, Inc.	0.75%	18,700
22	AXSM	Axsome Therapeutics, Inc.	0.60%	40,100
23	STO: SOBI	Swedish Orphan Biovitrum AB (publ)	0.57%	170,200
24	CAPR	Capricor Therapeutics, Inc.	0.56%	231,300
25	KYMR	Kymera Therapeutics, Inc.	0.49%	84,500

Showing 25 of 55 holdings

Subscribe to see the full list

Activate Now

As of Apr 30, 2026